Citations

Clear

219 citation(s) found for "Do, Ron".

Moral Distress and Moral Injury Among Attending Neurosurgeons: A National Survey
Mackel, Charles E. , Alterman, Ron L. , Buss, Mary K. , Reynolds, Renée M. , Spiotta, Alejandro M , Davis, Roger B. , Stippler, Martina , Fox, W Christopher

Mayo Clinic

Neurosurgery | March 23, 2022 | Volume: 91 | Issue: 1 | Pages: 59-65

10.1227/neu.0000000000001921 | PMID 35319531 Get It

BACKGROUND: “Moral distress” describes the psychological strain a provider faces when unable to uphold professional values because of external constraints. Recurrent or intense moral distress risks moral injury, burnout, and physician attrition but has not been systematically studied among neurosurgeons. OBJECTIVE: To develop a unique instrument to test moral distress among neurosurgeons, evaluate the frequency and intensity of scenarios that may elicit moral distress and injury, and determine their impact on neurosurgical burnout and turnover. METHODS: An online survey investigating moral distress, burnout, and practice patterns was emailed to attending neurosurgeon members of the Congress of Neurological Surgeons. Moral distress was evaluated through a novel survey designed for neurosurgical practice. RESULTS: A total of 173 neurosurgeons completed the survey. Half of neurosurgeons (47.7%) reported significant moral distress within the past year. The most common cause was managing critical patients lacking a clear treatment plan; the most intense distress was pressure from patient families to perform futile surgery. Multivariable analysis identified burnout and performing ≥2 futile surgeries per year as predictors of distress ( P < .001). Moral distress led 9.8% of neurosurgeons to leave a position and 26.6% to contemplate leaving. The novel moral distress survey demonstrated excellent internal consistency (Cronbach alpha = 0.89). CONCLUSION: We developed a reliable survey assessing neurosurgical moral distress. Nearly, half of neurosurgeons suffered moral distress within the past year, most intensely from external pressure to perform futile surgery. Moral distress correlated with burnout risk caused 10% of neurosurgeons to leave a position and a quarter to consider leaving.
Abstract 23085: 30-Day Outcomes of Transseptal Transcatheter Mitral Valve Replacement for Failed Surgical Bioprostheses (Mitral Valve-in-Valve): The MITRAL Trial (Mitral Implantation of TRAnscatheter vaLves)
Salinger, Michael H., Kodali, Susheel , Satler, Lowell F. , Inglessis, Ignacio, Eleid, Mackram F. , Meduri, Christopher, Rajagopal, Vivek , Reisman, Mark, Aldea, Gabriel S. , Eng, Marvin H. , Waksman, Ron , Pichard, Augusto D., Palacios, Igor F. , Russell, Hyde M., Saucedo, Jorge , Makkar, Raj , Rihal, Charanjit S. , Leon, Martin B. , Feldman, Ted , Guerrero, Mayra , Pursnani, Amit , Wang, Dee Dee , George, Isaac , Hahn, Rebecca T , Kar, Saibal , O’Neill, William W. , Rihal, Charanjit S.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 136 | Issue: suppl_1 | Pages: No page available

10.1161/circ.136.suppl_1.23085 Get It

Introduction: Transcatheter mitral valve replacement (TMVR) using aortic transcatheter heart valves (THV) is developing as an alternative to surgery for patients with severely degenerated mitral valve (MV) bioprostheses. Retrospective self-reported registries have collected outcomes on these TMVR procedures in the STS/ACC Transcatheter Valve Therapy Registry and in the Valve-in-Valve International Database. Most reported TMVR procedures for failed surgical bioprostheses have been performed using a transapical access approach. A prospective comprehensive evaluation of mitral Valve-in-Valve (VIV) outcomes, including transseptal access has not previously been conducted. Objectives: To evaluate in-hospital and 30-day clinical outcomes of transseptal mitral VIV with SAPIEN 3 THV in patients with very high surgical risk. Methods: Prospective enrollment of very high surgical risk patients with symptomatic severely degenerated MV surgical bioprostheses in 30 patients at 15 sites in the U.S. Candidates were assessed by a case review committee prior to approval. Baseline qualifying echocardiograms and cardiac CT studies were analyzed by independent core labs. Echocardiograms, cardiac CT studies and neurology evaluations were also performed after mitral VIV procedures. Clinical events were adjudicated by a clinical events committee and safety was monitored by a data safety monitoring board. Results: 26 patients have been enrolled between July 2016 and June 2017. Mean age was 83 years, 62% female, mean STS score was 10% and 62% were in New York Heart Association class III or IV. Transseptal access was used in all procedures. Technical success was achieved in all patients and there was no in-hospital mortality. There was no 30-day cardiovascular mortality and 4% (1 patient) 30-day all-cause mortality (1 patient died of asphyxia on day 29 after choking on pills at home), which was lower than the 30-day mortality in the TVT registry (9%). Detailed procedural, in-hospital and 30-day outcomes will be presented on the complete cohort of 30 patients. Conclusions: In patients without surgical alternatives, transseptal mitral ViV procedures in failed surgical bioprostheses are associated with high technical and procedural success and low 30-day mortality.
Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial
Brazg, Ron, Bhargava, Anuj , Thrasher, James, Latif, Kashif, Bode, Bruce W. , Bailey, Timothy S. , Horowitz, Barry , Cavale, Arvind R., Kudva, Yogish C. , Kaiserman, Kevin B. , Grunberger, George , Reed, John Chip, CHATTARAJ, SARNATH , ZHANG, GINA , Shin, John , Chen, Vivian , Lee, Scott W., Cordero, Toni L. , Rhinehart, Andrew S., Buckingham, Bruce A. , Bailey, Timothy S , Horowitz, Barry S , Kudva, Yogish C. , Cordero, Toni L , Vigersky, Robert A , Buckingham, Bruce , Garg, Satish K. , Reed, John H. Chip, Vigersky, Robert A.

Mayo Clinic

Diabetes Technology & Therapeutics | March 9, 2022 | Volume: 24 | Issue: 8 | Pages: 535-543

10.1089/dia.2021.0540 | PMID 35263188 Get It

Background: Standard insulin infusion sets (IISs) are to be replaced every 2 to 3 days to avoid complications and diabetic ketosis due to set failure. This pivotal trial evaluated the safety and performance of a new extended-wear infusion set (EIS) when used for 7 days by adults with type 1 diabetes (T1D). Methods: This single-arm, nonrandomized trial enrolled adults (18–80 years of age) with T1D, who used their own MiniMed™ 670G system with insulin lispro or insulin aspart and the EIS for up to 7 days, across 12 consecutive wears. Safety endpoints included incidence of serious adverse events (SAEs), serious adverse device effects (SADEs), unanticipated adverse device effects (UADEs), severe hypoglycemia (SevHypo), severe hyperglycemia (SevHyper), diabetic ketoacidosis (DKA), and skin infection. The EIS failure rate due to unexplained hyperglycemia (i.e., suspected occlusion), the overall EIS survival rate, glycemic control outcomes (i.e., A1C, mean sensor glucose and time spent in established glucose ranges), total daily insulin delivered, and satisfaction with the EIS were determined. Results: The intention to treat population ( n = 259, 48% men, 45.0 ± 14.1 years) wore a total of 3041 EIS devices. No SADE, UADE, or DKA events was reported. Overall rates of SAEs, SevHypo, SevHyper, and skin infection were 3.8, 2.5, 104.1, and 20.1 events per 100 participant-years. The rate of EIS failure due to unexplained hyperglycemia at the end of day 7 was 0.1% (95% confidence interval [CI]: 0.03–0.51) and 0.4% (95% CI: 0.16–1.00) for insulin lispro and aspart use, respectively. Overall EIS survival rate at the end of day 7 was 77.8% (95% CI: 76.2–79.3), glycemic control did not change, and participants reported greater satisfaction with the EIS compared with standard IISs worn before the study ( P < 0.001). Conclusions: This investigation demonstrates that the EIS, when worn for up to 7 days, was safe and rated with high satisfaction, without adversely affecting glycemic control in adults with T1D. Clinical Trial Registration number: NCT04113694 ( https://clinicaltrials.gov/ct2/show/NCT04113694 ).
A wearable cardioverter defibrillator with a low false alarm rate
Poole, Jeanne E. , Gleva, Marye J. , Birgersdotter‐Green, Ulrika , Branch, Kelley R. , Salam, Tariq , Crawford, Thomas , Willcox, Mark E. , Sridhar, Arun Mahankali, Mikdadi, Ghiath, Beinart, Sean C., Cha, Yong‐Mei , Russo, Andrea M. , Rowbotham, Ron, Sullivan, Joseph, Gustavson, Laura , Kivilaid, Kaisa, Salam, Tariq , Cha, Yong-Mei , Doshi, Rahul N.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | February 17, 2022 | Volume: 33 | Issue: 5 | Pages: 831-842

10.1111/jce.15417 | PMID 35174572 Get It

AbstractIntroductionA wearable cardioverter defibrillator (WCD) is indicated in appropriate patients to reduce the risk for sudden cardiac death. Challenges for patients wearing a WCD have been frequent false shock alarms primarily due to electrocardiogram noise and wear discomfort. The objective of this study was to test a contemporary WCD designed for reduced false shock alarms and improved comfort.MethodsOne hundred and thirty patients with left ventricular ejection fraction ≤40% and an active implantable cardioverter defibrillator (ICD) were fitted with the ASSURE WCD (Kestra Medical Technologies) and followed for 30 days. WCD detection was enabled and shock alarm markers recorded, but shocks and shock alarms were disabled. All WCD episodes and ICD ventricular tachycardia/ventricular fibrillation (VT/VF) episodes were adjudicated. The primary endpoint was the false‐positive shock alarm rate with a performance goal of 1 every 3.4 days (0.29 per patient‐day).ResultsOf 163 WCD episodes, 4 were VT/VF and 159 non‐VT/VF (121 rhythms with noise, 32 uncertain with noise, 6 atrial flutter without noise). Only three false‐positive shock alarm markers were recorded; one false‐positive shock alarm every 1333 patient‐days (0.00075 per patient‐day, 95% confidence interval: 0.00015–0.00361; p < .001). No ICD recorded VT/VF episodes meeting WCD detection criteria (≥170 bpm for ≥20 s) were missed by the WCD during 3501 patient‐days of use. Median wear was 31.0 days (interquartile range [IQR] 2.0) and median daily use 23.0 h (IQR 1.7). Adverse events were mostly mild: skin irritation (19.4%) and musculoskeletal discomfort (8.5%).ConclusionThe ASSURE WCD demonstrated a low false‐positive shock alarm rate, low patient‐reported discomfort, and no serious adverse events.
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Ma, Cynthia X., Luo, Jingqin , Freedman, Rachel A., Pluard, Timothy , Nangia, Julie R., Lu, Janice, Valdez-Albini, Frances, Cobleigh, Melody, Jones, Jason M., Lin, Nancy U. , Thomas, Shana, Anderson, Jill, Haas, Brittney, Bucheit, Leslie, Bryce, Richard , Lalani, Alshad S., Gao, Feng, Kimmick, Gretchen, Pegram, Mark D. , Bose, Ron , Cobleigh, Melody , Kimmick, Gretchen , Pluard, Timothy J , Winer, Eric , Marcom, Paul Kelly , Bryce, Richard , Carey, Lisa A , Goetz, Matthew P , Pegram, Mark D , Ellis, Matthew J , Bose, Ron , Lin, Nancy U , Luo, Jingqin , Ma, Cynthia X., Freedman, Rachel A., Nangia, Julie R., Lu, Janice, Valdez-Albini, Frances, Jones, Jason M., Thomas, Shana, Anderson, Jill, Haas, Brittney, Bucheit, Leslie, Lalani, Alshad S., Gao, Feng

Mayo Clinic

Clinical Cancer Research | January 19, 2022 | Volume: 28 | Issue: 7 | Pages: 1258-1267

10.1158/1078-0432.ccr-21-3418 | PMID 35046057 Get It

Abstract Purpose: HER2 mutations (HER2mut) induce endocrine resistance in estrogen receptor–positive (ER+) breast cancer. Patients and Methods: In this single-arm multi-cohort phase II trial, we evaluated the efficacy of neratinib plus fulvestrant in patients with ER+/HER2mut, HER2 non-amplified metastatic breast cancer (MBC) in the fulvestrant-treated (n = 24) or fulvestrant-naïve cohort (n = 11). Patients with ER-negative (ER−)/HER2mut MBC received neratinib monotherapy in an exploratory ER− cohort (n = 5). Results: The clinical benefit rate [CBR (95% confidence interval)] was 38% (18%–62%), 30% (7%–65%), and 25% (1%–81%) in the fulvestrant-treated, fulvestrant-naïve, and ER− cohorts, respectively. Adding trastuzumab at progression in 5 patients resulted in three partial responses and one stable disease ≥24 weeks. CBR appeared positively associated with lobular histology and negatively associated with HER2 L755 alterations. Acquired HER2mut were detected in 5 of 23 patients at progression. Conclusions: Neratinib and fulvestrant are active for ER+/HER2mut MBC. Our data support further evaluation of dual HER2 blockade for the treatment of HER2mut MBC.
Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum
Godara, Amandeep, Wang, Andy Y., Arkun, Knarik, Fogaren, Teresa, Qamar, Adnan S., McPhail, Ellen D., Kryzanski, James, Riesenburger, Ron, Comenzo, Raymond, Godara, Amandeep, Wang, Andy Y., Arkun, Knarik, Fogaren, Teresa, Qamar, Adnan S., McPhail, Ellen D., Kryzanski, James, Riesenburger, Ron, Comenzo, Raymond

Mayo Clinic

Surgical Neurology International | January 12, 2022 | Volume: 13 | Issue: No issue available | Pages: 12

10.25259/sni_1235_2021 | PMID 35127212 Get It

Background: Amyloidosis is a protein misfolding disorder that leads to the deposition of beta-pleated sheets of a fibrillar derivative of various protein precursors. Identification of the type of precursor protein is integral in treatment decision-making. The presence of two different types of amyloid in the same patient is unusually rare, and there are no previous reports of two different types of amyloid deposition in the ligamentum flavum (LF) in the same patient. Case Description: Here, we describe two patients with spinal stenosis who underwent laminectomies and were found to have AL and ATTR amyloid deposits in the LF. Conclusion: As the spine is becoming recognized as a site for ATTRwt amyloid deposition, patients undergoing spinal decompression surgery may potentially benefit from evaluation for amyloidosis in the LF.
Understanding Circadian Mechanisms of Sudden Cardiac Death: A Report From the National Heart, Lung, and Blood Institute Workshop, Part 1: Basic and Translational Aspects
Delisle, Brian P. , George, Alfred L. , Nerbonne, Jeanne M. , Bass, Joseph , Ripplinger, Crystal M. , Jain, Mukesh K. , Hermanstyne, Tracey O. , Young, Martin E. , Kannankeril, Prince J. , Duffy, Jeanne F. , Smolensky, Michael H. , Anafi, Ron C. , Scheer, Frank A. J. L. , Shivkumar, Kalyanam , Balijepalli, Ravi C. , Bass, Joseph T , Goldhaber, Joshua I. , Somers, Virend K. , Smolensky, Michael H , Garnett, Christine E , Anafi, Ron C , Scheer, Frank A J L , Shivkumar, Kalyanam , Shea, Steven A , Kannankeril, Prince J , George, Alfred L , Hall, Martica H. , Somers, Virend K.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | November 1, 2021 | Volume: 14 | Issue: 11 | Pages: No page available

10.1161/circep.121.010181 | PMID 34719240 Get It

Sudden cardiac death (SCD), the unexpected death due to acquired or genetic cardiovascular disease, follows distinct 24-hour patterns in occurrence. These 24-hour patterns likely reflect daily changes in arrhythmogenic triggers and the myocardial substrate caused by day/night rhythms in behavior, the environment, and endogenous circadian mechanisms. To better address fundamental questions regarding the circadian mechanisms, the National Heart, Lung, and Blood Institute convened a workshop, Understanding Circadian Mechanisms of Sudden Cardiac Death. We present a 2-part report of findings from this workshop. Part 1 summarizes the workshop and serves to identify research gaps and opportunities in the areas of basic and translational research. Among the gaps was the lack of standardization in animal studies for reporting environmental conditions (eg, timing of experiments relative to the light dark cycle or animal housing temperatures) that can impair rigor and reproducibility. Workshop participants also pointed to uncertainty regarding the importance of maintaining normal circadian rhythmic synchrony and the potential pathological impact of desynchrony on SCD risk. One related question raised was whether circadian mechanisms can be targeted to reduce SCD risk. Finally, the experts underscored the need for studies aimed at determining the physiological importance of circadian clocks in the many different cell types important to normal heart function and SCD. Addressing these gaps could lead to new therapeutic approaches/molecular targets that can mitigate the risk of SCD not only at certain times but over the entire 24-hour period.
Understanding Circadian Mechanisms of Sudden Cardiac Death: A Report From the National Heart, Lung, and Blood Institute Workshop, Part 2: Population and Clinical Considerations
Delisle, Brian P. , George, Alfred L. , Nerbonne, Jeanne M. , Bass, Joseph , Ripplinger, Crystal M. , Jain, Mukesh K. , Hermanstyne, Tracey O. , Young, Martin E. , Kannankeril, Prince J. , Duffy, Jeanne F. , Smolensky, Michael H. , Anafi, Ron C. , Scheer, Frank A. J. L. , Shivkumar, Kalyanam , Balijepalli, Ravi C. , Bass, Joseph T , Goldhaber, Joshua I. , Somers, Virend K. , Smolensky, Michael H , Garnett, Christine E , Anafi, Ron C , Scheer, Frank A J L , Shivkumar, Kalyanam , Shea, Steven A , Kannankeril, Prince J , George, Alfred L , Hall, Martica H. , Somers, Virend K.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | November 1, 2021 | Volume: 14 | Issue: 11 | Pages: No page available

10.1161/circep.121.010190 | PMID 34719257 Get It

Sudden cardiac death (SCD) is the sudden, unexpected death due to abrupt loss of heart function secondary to cardiovascular disease. In certain populations living with cardiovascular disease, SCD follows a distinct 24-hour pattern in occurrence, suggesting day/night rhythms in behavior, the environment, and endogenous circadian rhythms result in daily spans of increased vulnerability. The National Heart, Lung, and Blood Institute convened a workshop, Understanding Circadian Mechanisms of Sudden Cardiac Death to identify fundamental questions regarding the role of the circadian rhythms in SCD. Part 2 summarizes research gaps and opportunities in the areas of population and clinical research identified in the workshop. Established research supports a complex interaction between circadian rhythms and physiological responses that increase the risk for SCD. Moreover, these physiological responses themselves are influenced by several biological variables, including the type of cardiovascular disease, sex, age, and genetics, as well as environmental factors. The emergence of new noninvasive biotechnological tools that continuously measure key cardiovascular variables, as well as the identification of biomarkers to assess circadian rhythms, hold promise for generating large-scale human data sets that will delineate which subsets of individuals are most vulnerable to SCD. Additionally, these data will improve our understanding of how people who suffer from circadian disruptions develop cardiovascular diseases that increase the risk for SCD. Emerging strategies to identify new biomarkers that can quantify circadian health (eg, environmental, behavioral, and internal misalignment) may lead to new interventions and therapeutic targets to prevent the progression of cardiovascular diseases that cause SCD.